Moderna 2022 Priorities and Capital Allocation

Conclusion and next steps • . • The safety and reactogenicity profile of the 50 µg mRNA-1273.211 booster dose was comparable to the 50 µg mRNA-1273 booster vaccine We believe that the superiority shown by .211 confirms the potential of bivalent platform We continue to believe that bivalent booster will ensure the broadest immunity in face of evolutionary uncertainty for SARS-COV-2, maintaining current protection while expanding breadth and durability of neutralizing antibodies We anticipate 1 month (Day 29) data from Omicron-containing bivalent .214 booster in June 2022 Slide 21 moderna

View entire presentation